Form 4: iSpecimen Director Avtar Dhaliwal Reports Stock Option Grant

Director Avtar Dhaliwal reports the acquisition of stock options in iSpecimen Inc. following a reverse stock split.

Summary

• On September 27, 2024, Avtar Dhaliwal, a director of iSpecimen Inc. (ISPC), filed a Form 4 with the SEC.
• The form reports a transaction that occurred on September 25, 2024, where Dhaliwal acquired stock options.
• These options relate to 168 shares of iSpecimen's common stock.
• The exercise price for these options is $5.12 per share.
• The options were granted pursuant to the Issuer's Amended and Restated Stock Incentive Plan.
• The grant reflects the company's 20-for-1 reverse stock split, which became effective on September 13, 2024.
• The stock options vest in respect to 84 shares on each of September 30, 2024 and December 31, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which are a standard part of executive compensation. The reverse stock split is a neutral event in itself, often done to increase share price and maintain listing requirements.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule may incentivize the director to contribute to the company's success over the vesting period.

Industry Context

Stock option grants are a common practice in publicly traded companies to incentivize executives and align their interests with shareholders. The size and terms of the grant are typical for director-level compensation.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

Form 4, iSpecimen, ISPC, stock options, Avtar Dhaliwal, director, reverse stock split, beneficial ownership, SEC filing